Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial.
Nearly 10% of U.S. adults ages 18 to 49 have a chronic condition that puts them at risk of severe RSV disease, according to Pfizer. That number rises to around 24% for those aged 50 to 64. Pfizer also intends to present final results from the trial at an upcoming scientific conference and submit them for publication in a peer-reviewed journal.Pfizer said Tuesday its vaccine met the phase three trial's main goals for efficacy and safety in high-risk adults ages 50 to 59.
"The level of antibodies that you see after vaccination in those who are 18 to 60 are similar to those who are 60 and up," Munjal told CNBC. She later added that it "gives you confidence that across those two populations, they're actually responding to vaccine the same, and therefore are likely to have a similar efficacy."
Breaking News GSK Plc GSK Plc Science Pfizer Inc Health Care Industry Pharmaceuticals Biotechnology Biotech And Pharmaceuticals Business Business News
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Infant RSV Antibody Treatment Shows Strong ResultsThe new RSV antibody treatment for babies has been highly effective in its first season, according to a first look at data from four children’s hospitals.
Read more »
Take caution resuming your fitness routine after Covid, RSV or influenza, experts sayCovid, RSV and influenza require a thoughtful approach to rebooting exercise because they tend to cause whole-body inflammation. Experts share how to return safely.
Read more »
Risk for Preterm Birth Stops Maternal RSV Vaccine TrialWith a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns.
Read more »
Rising COVID Infections and Hospitalizations in the U.S. Amid Flu and RSV CasesCOVID infections and hospitalizations are rising as the U.S. goes through its first seasonal uptick after the end of the public health emergency, which as coming along with a rise in flu and RSV cases and creating a triple-threat of respiratory illnesses.
Read more »
Pfizer shutting down Everett plant, 119 employees out of workPfizer is closing a manufacturing facility in Everett, and 119 employees will lose their jobs.
Read more »
Johnson & Johnson is suing a former Philly-area employee, saying he took trade secrets to PfizerThe suit also alleges the employee violated his non-compete agreement when he took a job at Pfizer that is similar to the one he had at J&J.
Read more »